Imugene doses first cancer patient in Oasis trial
Join our daily newsletter At The Bell to receive exclusive market insights Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug. The clinical trial is …